Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder: A pragmatic, multi-site, double-blind, Randomized, placebo-controlled, trial (TAB).

Funded by the NIH HEAL Initiative℠

Buprenorphine is an evidence-based treatment for opioid use disorder. However, buprenorphine, as a stand-alone pharmacotherapy, has limitations including challenges with treatment retention and patient experiences of craving for, and/or use of, illicit opioids and other substances. Research suggests that glucagon-like peptide-1 (GLP-1) agonists may ameliorate substance craving and use. The TAB trial will test tirzepatide, which is a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist, as an adjunct to buprenorphine for the treatment of opioid use disorder.